Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Global Epidemiology, Clinical Features, Diagnosis and Current Therapeutic Novelties in Migraine Therapy and their Prevention: A Narrative Review

Author(s): Mohammad Daud Ali*, Fehmida Gayasuddin Qur, Md. Sarfaraz Alam, Nawaf M. Alotaibi and Md. Ali Mujtaba

Volume 29, Issue 41, 2023

Published on: 14 December, 2023

Page: [3295 - 3311] Pages: 17

DOI: 10.2174/0113816128266227231205114320

Price: $65

Abstract

Introduction: The current article reviews the latest information on epidemiology, clinical features, diagnosis, recent advancements in clinical management, current therapeutic novelties, and the prevention of migraines. In a narrative review, all studies as per developed MeSH terms published until February 2023, excluding those irrelevant, were identified through a PubMed literature search.

Methods: Overall, migraine affects more than a billion people annually and is one of the most common neurological illnesses. A wide range of comorbidities is associated with migraines, including stress and sleep disturbances. To lower the worldwide burden of migraine, comprehensive efforts are required to develop and enhance migraine treatment, which is supported by informed healthcare policy. Numerous migraine therapies have been successful, but not all patients benefit from them.

Results: CGRP pathway-targeted therapy demonstrates the importance of translating mechanistic understanding into effective treatment. In this review, we discuss clinical features, diagnosis, and recently approved drugs, as well as a number of potential therapeutic targets, including pituitary adenylate cyclase-activating polypeptide (PACAP), adenosine, opioid receptors, potassium channels, transient receptor potential ion channels (TRP), and acid-sensing ion channels (ASIC).

Conclusion: In addition to providing more treatment options for improved clinical care, a better understanding of these mechanisms facilitates the discovery of novel therapeutic targets.

Keywords: Migraine, epidemiology, acute treatment, preventive treatment, clinical features.

« Previous Next »
[1]
Steiner TJ, Stovner LJ. Global epidemiology of migraine and its implications for public health and health policy. Nat Rev Neurol 2023; 19(2): 109-17.
[http://dx.doi.org/10.1038/s41582-022-00763-1] [PMID: 36693999]
[2]
Lipton RB, Bigal ME. Ten lessons on the epidemiology of migraine. Headache 2007; 47(s1) (Suppl. 1): S2-9.
[http://dx.doi.org/10.1111/j.1526-4610.2007.00671.x] [PMID: 17425705]
[3]
Minen M, Shome A, Halpern A, et al. A migraine management training program for primary care providers: An overview of a survey and pilot study findings, lessons learned, and considerations for further research. Headache 2016; 56(4): 725-40.
[http://dx.doi.org/10.1111/head.12803] [PMID: 27037903]
[4]
Buse DC, Loder EW, Gorman JA, et al. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: Results of the American Migraine Prevalence and Prevention (AMPP) study. Headache 2013; 53(8): 1278-99.
[http://dx.doi.org/10.1111/head.12150] [PMID: 23808666]
[5]
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68(5): 343-9.
[http://dx.doi.org/10.1212/01.wnl.0000252808.97649.21] [PMID: 17261680]
[6]
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders. Cephalalgia 2018; 38(1): 1-211.
[http://dx.doi.org/10.1177/0333102417738202]
[7]
Ashina M, Buse DC, Ashina H, et al. Migraine: Integrated approaches to clinical management and emerging treatments. Lancet 2021; 397(10283): 1505-18.
[http://dx.doi.org/10.1016/S0140-6736(20)32342-4] [PMID: 33773612]
[8]
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders 3rd edition (beta version). Cephalalgia 2013; 33(9): 629-808.
[http://dx.doi.org/10.1177/0333102413485658]
[9]
Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ. Poor medical care for people with migraine in Europe – Evidence from the Eurolight study. J Headache Pain 2018; 19(1): 10.
[http://dx.doi.org/10.1186/s10194-018-0839-1] [PMID: 29392600]
[10]
Ashina M, Katsarava Z, Do TP, et al. Migraine: Epidemiology and systems of care. Lancet 2021; 397(10283): 1485-95.
[http://dx.doi.org/10.1016/S0140-6736(20)32160-7] [PMID: 33773613]
[11]
Hepp Z, Dodick DW, Varon SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis. Cephalalgia 2017; 37(5): 470-85.
[http://dx.doi.org/10.1177/0333102416678382] [PMID: 27837173]
[12]
American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 2019; 59(1): 1-18.
[13]
Safiri S, Pourfathi H, Eagan A, et al. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain 2022; 163(2): e293-309.
[http://dx.doi.org/10.1097/j.pain.0000000000002275] [PMID: 34001771]
[14]
IHME. GBD Results Tool 2020. Available From: http://ghdx.healthdata.org/gbd-results
[15]
Institute for Health Metrics and Evaluation. 2020. Available From: https://mailchi.mp/ healthdata/07022020-2871488?e=99a49e288b
[16]
Diseases and injuries collaborators global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the global burden of disease study 2019. Lancet 2019; 2000(396): 1204-22.
[http://dx.doi.org/10.1016/S0140-6736(20)30925-9]
[17]
Bigal ME, Lipton RB. Clinical course in migraine: Conceptualizing migraine transformation. Neurology 2008; 71(11): 848-55.
[http://dx.doi.org/10.1212/01.wnl.0000325565.63526.d2] [PMID: 18779513]
[18]
Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: Results from the American Migraine Prevalence and Prevention Study. Headache 2012; 52(10): 1456-70.
[http://dx.doi.org/10.1111/j.1526-4610.2012.02223.x] [PMID: 22830411]
[19]
Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache 2022; 62(1): 111-2.
[20]
Serrano D, Lipton RB, Scher AI, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: Implications for diagnosis, treatment and clinical trial design. J Headache Pain 2017; 18(1): 101.
[http://dx.doi.org/10.1186/s10194-017-0787-1] [PMID: 28980171]
[21]
Bigal ME, Lipton RB. Migraine chronification. Curr Neurol Neurosci Rep 2011; 11(2): 139-48.
[http://dx.doi.org/10.1007/s11910-010-0175-6] [PMID: 21243447]
[22]
Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache 2008; 48(8): 1157-68.
[http://dx.doi.org/10.1111/j.1526-4610.2008.01217.x] [PMID: 18808500]
[23]
Manack A, Buse DC, Serrano D, Turkel CC, Lipton RB. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology 2011; 76(8): 711-8.
[http://dx.doi.org/10.1212/WNL.0b013e31820d8af2] [PMID: 21270413]
[24]
Lipton RB, Munjal S, Buse DC, Fanning KM, Bennett A, Reed ML. Predicting Inadequate response to acute migraine medication: Results from the American migraine prevalence and prevention (AMPP) study. Headache 2016; 56(10): 1635-48.
[http://dx.doi.org/10.1111/head.12941] [PMID: 27731896]
[25]
Buse DC, Greisman JD, Baigi K, Lipton RB. Migraine progression: A systematic review. Headache 2019; 59(3): 306-38.
[http://dx.doi.org/10.1111/head.13459] [PMID: 30589090]
[26]
Evans RW. Diagnostic testing for migraine and other primary headaches. Neurol Clin 2019; 37(4): 707-25.
[http://dx.doi.org/10.1016/j.ncl.2019.08.001] [PMID: 31563228]
[27]
Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: The American Headache Society evidence assessment of migraine pharmacotherapies. Headache 2015; 55(1): 3-20.
[http://dx.doi.org/10.1111/head.12499] [PMID: 25600718]
[28]
Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Neurology 2016; 86(19): 1818-26.
[http://dx.doi.org/10.1212/WNL.0000000000002560] [PMID: 27164716]
[29]
Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: New drugs, new hope? J Headache Pain 2019; 20(1): 37.
[http://dx.doi.org/10.1186/s10194-019-0974-3]
[30]
Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78(17): 1337-45.
[http://dx.doi.org/10.1212/WNL.0b013e3182535d20] [PMID: 22529202]
[31]
Reddy DS. The pathophysiological and pharmacological basis of current drug treatment of migraine headache. Expert Rev Clin Pharmacol 2013; 6(3): 271-88.
[http://dx.doi.org/10.1586/ecp.13.14] [PMID: 23656340]
[32]
American Migraine Foundation. How Gepants and Ditans Complement Existing Therapies. 2020-2023. Available From: https://americanmigrainefoundation.org/resource-library/gepants-ditans-therapies/#:~:text=Ditans%20and%20gepants%20are%20both,sound%20sensitivity%2C%20nausea%20and%20vomiting
[33]
Pringsheim T, Davenport WJ, Marmura MJ, Schwedt TJ, Silberstein S. How to apply the AHS evidence assessment of the acute treatment of migraine in adults to your patient with migraine. Headache 2016; 56(7): 1194-200.
[http://dx.doi.org/10.1111/head.12870] [PMID: 27322907]
[34]
Buse DC, Rupnow MFT, Lipton RB. Assessing and managing all aspects of migraine: Migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc 2009; 84(5): 422-35.
[http://dx.doi.org/10.1016/S0025-6196(11)60561-2] [PMID: 19411439]
[35]
Diener HC, Tassorelli C, Dodick DW. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults Fourth edition. Cephalalgia 2019; 39: pp. (6)687-710.
[http://dx.doi.org/10.1177/0333102419828967]
[36]
Worthington I, Pringsheim T, Gawel MJ, et al. Canadian Headache Society Guideline: Acute drug therapy for migraine headache. Can J Neurol Sci 2013; 40(S3) (Suppl. 3): S1-3.
[http://dx.doi.org/10.1017/S0317167100118943] [PMID: 23968886]
[37]
Evers S, Áfra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - Revised report of an EFNS task force. Eur J Neurol 2009; 16(9): 968-81.
[http://dx.doi.org/10.1111/j.1468-1331.2009.02748.x] [PMID: 19708964]
[38]
Lipton RB, Buse DC, Serrano D, Holland S, Reed ML. Examination of unmet treatment needs among persons with episodic migraine: Results of the American Migraine Prevalence and Prevention (AMPP) study. Headache 2013; 53(8): 1300-11.
[http://dx.doi.org/10.1111/head.12154] [PMID: 23879870]
[39]
WHO. Lifting The Burden 2011. Available From: https://apps.who.int/iris/handle/10665/44571
[40]
Steiner TJ, Jensen R, Katsarava Z. Aids to management of headache disorders in primary care 2nd edition): On behalf of the European Headache Federation and Lifting The Burden: The Global Campaign against Headache. J Headache Pain 2019; 20: p. (1)57.
[http://dx.doi.org/10.1186/s10194-018-0899-2]
[41]
Rabbie R, Derry S, Moore RA. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Libr 2013; 2019(5): CD008039.
[http://dx.doi.org/10.1002/14651858.CD008039.pub3] [PMID: 23633348]
[42]
Kirthi V, Derry S, Moore RA. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Libr 2013; 2019(5): CD008041.
[http://dx.doi.org/10.1002/14651858.CD008041.pub3] [PMID: 23633350]
[43]
Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults - Overview of Cochrane reviews. Cochrane Libr 2014; 2019(5): CD009108.
[http://dx.doi.org/10.1002/14651858.CD009108.pub2] [PMID: 24865446]
[44]
Dahlöf CGH. Infrequent or non-response to oral sumatriptan does not predict response to other triptans-review of four trials. Cephalalgia 2006; 26(2): 98-106.
[http://dx.doi.org/10.1111/j.1468-2982.2005.01010.x] [PMID: 16426262]
[45]
Law S, Derry S, Moore RA. Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. Cochrane Libr 2016; 4(4): CD008541.
[http://dx.doi.org/10.1002/14651858.CD008541.pub3] [PMID: 27096438]
[46]
Géraud G, Keywood C, Senard JM. Migraine headache recurrence: Relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003; 43(4): 376-88.
[http://dx.doi.org/10.1046/j.1526-4610.2003.03073.x] [PMID: 12656709]
[47]
Miller S. The acute and preventative treatment of episodic migraine. Ann Indian Acad Neurol 2012; 15(5) (Suppl. 1): 33.
[http://dx.doi.org/10.4103/0972-2327.99998] [PMID: 23024562]
[48]
Tfelt-Hansen P, Saxena PR, Dahlöf C, et al. Ergotamine in the acute treatment of migraine: A review and European consensus. Brain 2000; 123(1): 9-18.
[http://dx.doi.org/10.1093/brain/123.1.9] [PMID: 10611116]
[49]
Winner P, Hershey AD. Epidemiology and diagnosis of migraine in children. Curr Pain Headache Rep 2007; 11(5): 375-82.
[http://dx.doi.org/10.1007/s11916-007-0220-6] [PMID: 17894928]
[50]
Oskoui M, Pringsheim T, Holler-Managan Y, et al. Practice guideline update summary: Acute treatment of migraine in children and adolescents. Neurology 2019; 93(11): 487-99.
[http://dx.doi.org/10.1212/WNL.0000000000008095] [PMID: 31413171]
[51]
Oskoui M, Pringsheim T, Billinghurst L, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention. Neurology 2019; 93(11): 500-9.
[http://dx.doi.org/10.1212/WNL.0000000000008105] [PMID: 31413170]
[52]
Westergaard MLS, Steiner TJ, MacGregor EA, et al. The Headache Under-Response to Treatment (HURT) questionnaire: Assessment of utility in headache specialist care. Cephalalgia 2013; 33(4): 245-55.
[http://dx.doi.org/10.1177/0333102412469740] [PMID: 23236098]
[53]
Vetvik KG, MacGregor EA, Lundqvist C, Russell MB. Self-reported menstrual migraine in the general population. J Headache Pain 2010; 11(2): 87-92.
[http://dx.doi.org/10.1007/s10194-010-0197-0] [PMID: 20186561]
[54]
Vetvik KG, MacGregor EA. Menstrual migraine: A distinct disorder needing greater recognition. Lancet Neurol 2021; 20(4): 304-15.
[http://dx.doi.org/10.1016/S1474-4422(20)30482-8] [PMID: 33600767]
[55]
Hu Y, Guan X, Fan L, Jin L. Triptans in prevention of menstrual migraine: A systematic review with meta-analysis. J Headache Pain 2013; 14(1): 7.
[http://dx.doi.org/10.1186/1129-2377-14-7] [PMID: 23565873]
[56]
MacGregor EA. Migraine, menopause and hormone replacement therapy. Post Reprod Health 2018; 24(1): 11-8.
[http://dx.doi.org/10.1177/2053369117731172] [PMID: 28994639]
[57]
Amundsen S, Nordeng H, Nezvalová-Henriksen K, Stovner LJ, Spigset O. Pharmacological treatment of migraine during pregnancy and breastfeeding. Nat Rev Neurol 2015; 11(4): 209-19.
[http://dx.doi.org/10.1038/nrneurol.2015.29] [PMID: 25776823]
[58]
Dodick DW, Freitag F, Banks J, et al. Topiramate versus amitriptyline in migraine prevention: A 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 2009; 31(3): 542-59.
[http://dx.doi.org/10.1016/j.clinthera.2009.03.020] [PMID: 19393844]
[59]
Banzi R, Cusi C, Randazzo C, Sterzi R, Tedesco D, Moja L. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults. Cochrane Libr 2015; 2019(11): CD002919.
[http://dx.doi.org/10.1002/14651858.CD002919.pub3] [PMID: 25829028]
[60]
Pringsheim T, Davenport W, Mackie G, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci 2012; 39(2) (Suppl. 2): S1-S59.
[PMID: 22683887]
[61]
Stovner LJ, Linde M, Gravdahl GB, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia 2014; 34(7): 523-32.
[http://dx.doi.org/10.1177/0333102413515348] [PMID: 24335848]
[62]
Linde M, Mulleners WM, Chronicle EP, McCrory DC. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Libr 2013; 2016(5): CD010610.
[http://dx.doi.org/10.1002/14651858.CD010610] [PMID: 23797676]
[63]
Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial. Headache 2007; 47(2): 170-80.
[http://dx.doi.org/10.1111/j.1526-4610.2006.00684.x] [PMID: 17300356]
[64]
Jackson JL, Cogbill E, Santana-Davila R, et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One 2015; 10(7): e0130733.
[http://dx.doi.org/10.1371/journal.pone.0130733] [PMID: 26172390]
[65]
Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med 2002; 346(4): 257-70.
[http://dx.doi.org/10.1056/NEJMra010917] [PMID: 11807151]
[66]
Humphrey PPA, Feniuk W, Perren MJ, Beresford IJM, Skingle M, Whalley ET. Serotonin and migraine. Ann N Y Acad Sci 1990; 600(1): 587-98.
[http://dx.doi.org/10.1111/j.1749-6632.1990.tb16912.x] [PMID: 2252337]
[67]
Goadsby PJ. The vascular theory of migraine - A great story wrecked by the facts. Brain 2009; 132(1): 6-7.
[http://dx.doi.org/10.1093/brain/awn321] [PMID: 19098031]
[68]
Hou M, Kanje M, Longmore J, Tajti J, Uddman R, Edvinsson L. 5-HT1B and 5-HT1D receptors in the human trigeminal ganglion: Co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res 2001; 909(1-2): 112-20.
[http://dx.doi.org/10.1016/S0006-8993(01)02645-2] [PMID: 11478927]
[69]
Gomez-Mancilla B, Cutler NR, Leibowitz MT, et al. Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia 2001; 21(7): 727-32.
[http://dx.doi.org/10.1046/j.1468-2982.2001.00208.x] [PMID: 11595000]
[70]
Ma QP. Co-localization of 5-HT1B/1D/1F receptors and glutamate in trigeminal ganglia in rats. Neuroreport 2001; 12(8): 1589-91.
[http://dx.doi.org/10.1097/00001756-200106130-00015] [PMID: 11409721]
[71]
Vila-Pueyo M. Targeted 5-HT1F therapies for migraine. Neurotherapeutics 2018; 15(2): 291-303.
[http://dx.doi.org/10.1007/s13311-018-0615-6] [PMID: 29488143]
[72]
Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 2010; 30(10): 1159-69.
[http://dx.doi.org/10.1177/0333102410370873] [PMID: 20855361]
[73]
Oswald JC, Schuster NM. Lasmiditan for the treatment of acute migraine: A review and potential role in clinical practice. J Pain Res 2018; 11: 2221-7.
[http://dx.doi.org/10.2147/JPR.S152216] [PMID: 30323656]
[74]
Negro A, Lionetto L, Simmaco M, Martelletti P. CGRP receptor antagonists: An expanding drug class for acute migraine? Expert Opin Investig Drugs 2012; 21(6): 807-18.
[http://dx.doi.org/10.1517/13543784.2012.681044] [PMID: 22512641]
[75]
Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs 2019; 28(6): 555-67.
[http://dx.doi.org/10.1080/13543784.2019.1618830] [PMID: 31081399]
[76]
Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: A disorder of sensory processing. Physiol Rev 2017; 97(2): 553-622.
[http://dx.doi.org/10.1152/physrev.00034.2015] [PMID: 28179394]
[77]
Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: A new era in migraine therapy. Lancet 2019; 394(10210): 1765-74.
[http://dx.doi.org/10.1016/S0140-6736(19)32504-8] [PMID: 31668411]
[78]
Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: A randomised, double-blind, placebo-controlled, phase 3b study. Lancet 2018; 392(10161): 2280-7.
[http://dx.doi.org/10.1016/S0140-6736(18)32534-0] [PMID: 30360965]
[79]
Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): A randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 2019; 394(10203): 1030-40.
[http://dx.doi.org/10.1016/S0140-6736(19)31946-4] [PMID: 31427046]
[80]
Ruff DD, Ford JH, Tockhorn-Heidenreich A, et al. Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: Results from two global randomized clinical trials. Eur J Neurol 2020; 27(4): 609-18.
[http://dx.doi.org/10.1111/ene.14114] [PMID: 31692188]
[81]
MaassenVanDenBrink A. Meijer J, Villalón CM, Ferrari MD. Wiping out CGRP: Potential cardiovascular risks. Trends Pharmacol Sci 2016; 37(9): 779-88.
[http://dx.doi.org/10.1016/j.tips.2016.06.002]
[82]
Lambru G, Hill B, Murphy M, Tylova I, Andreou AP. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 2020; 21(1): 61.
[http://dx.doi.org/10.1186/s10194-020-01127-0] [PMID: 32487102]
[83]
Russo A, Silvestro M, Scotto di Clemente F, et al. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: A comprehensive real-world experience. J Headache Pain 2020; 21(1): 69.
[http://dx.doi.org/10.1186/s10194-020-01143-0] [PMID: 32517693]
[84]
Miyata A, Jiang L, Dahl RD, et al. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 1990; 170(2): 643-8.
[http://dx.doi.org/10.1016/0006-291X(90)92140-U] [PMID: 2383262]
[85]
Rustichelli C, Lo Castro F, Baraldi C, Ferrari A. Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: A brief review. Expert Opin Investig Drugs 2020; 29(11): 1269-75.
[http://dx.doi.org/10.1080/13543784.2020.1811966] [PMID: 32877252]
[86]
Julius D. TRP channels and pain. Annu Rev Cell Dev Biol 2013; 29(1): 355-84.
[http://dx.doi.org/10.1146/annurev-cellbio-101011-155833] [PMID: 24099085]
[87]
Shimizu T, Toriumi H, Sato H, et al. Distribution and origin of TRPV1 receptor-containing nerve fibers in the dura mater of rat. Brain Res 2007; 1173: 84-91.
[http://dx.doi.org/10.1016/j.brainres.2007.07.068] [PMID: 17765209]
[88]
Huang D, Li S, Dhaka A, Story GM, Cao YQ. Expression of the transient receptor potential channels TRPV1, TRPA1 and TRPM8 in mouse trigeminal primary afferent neurons innervating the dura. Mol Pain 2012; 8: 1744-8069-8-66.
[http://dx.doi.org/10.1186/1744-8069-8-66] [PMID: 22971321]
[89]
Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications. Cephalalgia 2019; 39(3): 445-58.
[http://dx.doi.org/10.1177/0333102418821662] [PMID: 30661365]
[90]
Albrecht D, Iwashima M, Dillon D, Harris S, Levy J. A phase 1, randomized, open‐label, safety, tolerability, and comparative bioavailability study of intranasal dihydroergotamine powder (STS101), intramuscular dihydroergotamine mesylate, and intranasal DHE mesylate spray in healthy adult subjects. Headache 2020; 60(4): 701-12.
[http://dx.doi.org/10.1111/head.13737] [PMID: 31985049]
[91]
Waldmann R, Champigny G, Bassilana F, Heurteaux C, Lazdunski M. A proton-gated cation channel involved in acid-sensing. Nature 1997; 386(6621): 173-7.
[http://dx.doi.org/10.1038/386173a0] [PMID: 9062189]
[92]
Wemmie JA, Taugher RJ, Kreple CJ. Acid-sensing ion channels in pain and disease. Nat Rev Neurosci 2013; 14(7): 461-71.
[http://dx.doi.org/10.1038/nrn3529] [PMID: 23783197]
[93]
Baron A, Lingueglia E. Pharmacology of acid-sensing ion channels – Physiological and therapeutical perspectives. Neuropharmacology 2015; 94: 19-35.
[http://dx.doi.org/10.1016/j.neuropharm.2015.01.005] [PMID: 25613302]
[94]
Cristofori-Armstrong B, Rash LD. Acid-sensing ion channel (ASIC) structure and function: Insights from spider, snake and sea anemone venoms. Neuropharmacology 2017; 127: 173-84.
[http://dx.doi.org/10.1016/j.neuropharm.2017.04.042] [PMID: 28457973]
[95]
Waldmann R, Champigny G, Voilley N, Lauritzen I, Lazdunski M. The mammalian degenerin MDEG, an amiloride-sensitive cation channel activated by mutations causing neurodegeneration in Caenorhabditis elegans. J Biol Chem 1996; 271(18): 10433-6.
[http://dx.doi.org/10.1074/jbc.271.18.10433] [PMID: 8631835]
[96]
Yu Y, Chen Z, Li WG, et al. A nonproton ligand sensor in the acid-sensing ion channel. Neuron 2010; 68(1): 61-72.
[http://dx.doi.org/10.1016/j.neuron.2010.09.001] [PMID: 20920791]
[97]
Li WG, Yu Y, Zhang ZD, Cao H, Xu TL. ASIC3 channels integrate agmatine and multiple inflammatory signals through the nonproton ligand sensing domain. Mol Pain 2010; 6(6): 1744-8069-6-88.
[http://dx.doi.org/10.1186/1744-8069-6-88] [PMID: 21143836]
[98]
Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - Successful translation from bench to clinic. Nat Rev Neurol 2018; 14(6): 338-50.
[http://dx.doi.org/10.1038/s41582-018-0003-1] [PMID: 29691490]
[99]
Bernstein C, Burstein R. Sensitization of the trigeminovascular pathway: Perspective and implications to migraine pathophysiology. J Clin Neurol 2012; 8(2): 89-99.
[http://dx.doi.org/10.3988/jcn.2012.8.2.89] [PMID: 22787491]
[100]
Khan S, Mohammad Amin F. Meningeal contribution to migraine pain: A magnetic resonance angiography study. Brain 2019; 142(1): 93-102.
[http://dx.doi.org/10.1093/brain/awy300]
[101]
Akerman S, Holland PR, Lasalandra MP, Goadsby PJ. Inhibition of trigeminovascular dural nociceptive afferents by Ca2+-activated K+ (MaxiK/BKCa) channel opening. Pain 2010; 151(1): 128-36.
[http://dx.doi.org/10.1016/j.pain.2010.06.028] [PMID: 20655661]
[102]
Guo Z, Cao YQ. Over-expression of TRESK K(+) channels reduces the excitability of trigeminal ganglion nociceptors. PLoS One 2014; 9(1): e87029.
[http://dx.doi.org/10.1371/journal.pone.0087029] [PMID: 24466320]
[103]
Lafrenière RG, Cader MZ, Poulin JF, et al. A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura. Nat Med 2010; 16(10): 1157-60.
[http://dx.doi.org/10.1038/nm.2216] [PMID: 20871611]
[104]
Wulf-Johansson H, Amrutkar DV, Hay-Schmidt A, et al. Localization of large conductance calcium-activated potassium channels and their effect on calcitonin gene-related peptide release in the rat trigemino–neuronal pathway. Neuroscience 2010; 167(4): 1091-102.
[http://dx.doi.org/10.1016/j.neuroscience.2010.02.063] [PMID: 20211697]
[105]
Belloni FL, Hintze TH. Glibenclamide attenuates adenosine-induced bradycardia and coronary vasodilatation. Am J Physiol Heart Circ Physiol 1991; 261(3): H720-7.
[http://dx.doi.org/10.1152/ajpheart.1991.261.3.H720] [PMID: 1909503]
[106]
Farzaneh T, Tinker A. Differences in the mechanism of metabolic regulation of ATP-sensitive K+ channels containing Kir6.1 and Kir6.2 subunits. Cardiovasc Res 2008; 79(4): 621-31.
[http://dx.doi.org/10.1093/cvr/cvn138] [PMID: 18522960]
[107]
Hibino H, Inanobe A, Furutani K, Murakami S, Findlay I, Kurachi Y. Inwardly rectifying potassium channels: Their structure, function, and physiological roles. Physiol Rev 2010; 90(1): 291-366.
[http://dx.doi.org/10.1152/physrev.00021.2009] [PMID: 20086079]
[108]
Kleppisch T, Nelson MT. Adenosine activates ATP-sensitive potassium channels in arterial myocytes via A2 receptors and cAMP-dependent protein kinase. Proc Natl Acad Sci USA 1995; 92(26): 12441-5.
[http://dx.doi.org/10.1073/pnas.92.26.12441] [PMID: 8618917]
[109]
Aguilar-Bryan L, Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr Rev 1999; 20(2): 101-35.
[http://dx.doi.org/10.1210/edrv.20.2.0361] [PMID: 10204114]
[110]
Brayden JE. Functional roles of KATP channels in vascular smooth muscle. Clin Exp Pharmacol Physiol 2002; 29(4): 312-6.
[http://dx.doi.org/10.1046/j.1440-1681.2002.03650.x] [PMID: 11985542]
[111]
Yamada K, Inagaki N. Neuroprotection by K channels. J Mol Cell Cardiol 2005; 38(6): 945-9.
[http://dx.doi.org/10.1016/j.yjmcc.2004.11.020] [PMID: 15910879]
[112]
Al-Karagholi MAM, Ghanizada H, Hansen JM, et al. Levcromakalim, an adenosine triphosphate‐sensitive potassium channel opener, dilates extracerebral but not cerebral arteries. Headache 2019; 59(9): 1468-80.
[http://dx.doi.org/10.1111/head.13634] [PMID: 31535367]
[113]
Al-Karagholi MAM, Ghanizada H, Nielsen CAW, Hougaard A, Ashina M. Opening of ATP sensitive potassium channels causes migraine attacks with aura. Brain 2021; 144(8): 2322-32.
[http://dx.doi.org/10.1093/brain/awab136] [PMID: 33768245]
[114]
Al-Karagholi MAM, Hansen JM, Guo S, Olesen J, Ashina M. Opening of ATP-sensitive potassium channels causes migraine attacks: A new target for the treatment of migraine. Brain 2019; 142(9): 2644-54.
[http://dx.doi.org/10.1093/brain/awz199] [PMID: 31292608]
[115]
Tabrizchi R, Bedi S. Pharmacology of adenosine receptors in the vasculature. Pharmacol Ther 2001; 91(2): 133-47.
[http://dx.doi.org/10.1016/S0163-7258(01)00152-8] [PMID: 11728606]
[116]
Sawynok J. Adenosine receptor targets for pain. Neuroscience 2016; 338: 1-18.
[http://dx.doi.org/10.1016/j.neuroscience.2015.10.031] [PMID: 26500181]
[117]
Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006; 5(3): 247-64.
[http://dx.doi.org/10.1038/nrd1983] [PMID: 16518376]
[118]
Jacobson KA, Tosh DK, Jain S, Gao ZG. Historical and current adenosine receptor agonists in preclinical and clinical development. Front Cell Neurosci 2019; 13: 124.
[http://dx.doi.org/10.3389/fncel.2019.00124] [PMID: 30983976]
[119]
Fried N, Elliott M, Oshinsky M. The role of adenosine signaling in headache: A review. Brain Sci 2017; 7(12): 30.
[http://dx.doi.org/10.3390/brainsci7030030] [PMID: 28335379]
[120]
Sachdeva S, Gupta M. Adenosine and its receptors as therapeutic targets: An overview. Saudi Pharm J 2013; 21(3): 245-53.
[http://dx.doi.org/10.1016/j.jsps.2012.05.011] [PMID: 23960840]
[121]
Carruthers AM, Sellers LA, Jenkins DW, Jarvie EM, Feniuk W, Humphrey PPA. Adenosine A(1) receptor-mediated inhibition of protein kinase A-induced calcitonin gene-related peptide release from rat trigeminal neurons. Mol Pharmacol 2001; 59(6): 1533-41.
[http://dx.doi.org/10.1124/mol.59.6.1533] [PMID: 11353815]
[122]
Lu W, Li B, Chen J, et al. Expression of calcitonin gene-related peptide, adenosine A2a receptor and adenosine A1 receptor in experiment rat migraine models. Biomed Rep 2016; 4(3): 379-83.
[http://dx.doi.org/10.3892/br.2016.591] [PMID: 26998280]
[123]
Goadsby PJ, Hoskin KL, Storer RJ, Edvinsson L, Connor HE. Adenosine A1 receptor agonists inhibit trigeminovascular nociceptive transmission. Brain 2002; 125(6): 1392-401.
[http://dx.doi.org/10.1093/brain/awf141] [PMID: 12023327]
[124]
Haanes KA, Labastida-Ramírez A, Chan KY, et al. Characterization of the trigeminovascular actions of several adenosine A2A receptor antagonists in an in vivo rat model of migraine. J Headache Pain 2018; 19(1): 41.
[http://dx.doi.org/10.1186/s10194-018-0867-x] [PMID: 29802484]
[125]
Moye LS, Tipton AF, Dripps I, et al. Delta opioid receptor agonists are effective for multiple types of headache disorders. Neuropharmacology 2019; 148: 77-86.
[http://dx.doi.org/10.1016/j.neuropharm.2018.12.017] [PMID: 30553828]
[126]
Danielsson I, Gasior M, Stevenson G, Folk J, Rice K, Negus S. Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys. Pharmacol Biochem Behav 2006; 85(2): 428-34.
[http://dx.doi.org/10.1016/j.pbb.2006.09.012] [PMID: 17112570]
[127]
Chu Sin Chung P, Boehrer A, Stephan A, et al. Delta opioid receptors expressed in forebrain GABAergic neurons are responsible for SNC80-induced seizures. Behav Brain Res 2015; 278: 429-34.
[http://dx.doi.org/10.1016/j.bbr.2014.10.029] [PMID: 25447299]
[128]
Spahn V, Stein C. Targeting delta opioid receptors for pain treatment: Drugs in phase I and II clinical development. Expert Opin Investig Drugs 2017; 26(2): 155-60.
[http://dx.doi.org/10.1080/13543784.2017.1275562] [PMID: 28001096]
[129]
Dripps IJ, Boyer BT, Neubig RR, Rice KC, Traynor JR, Jutkiewicz EM. Role of signalling molecules in behaviours mediated by the δ opioid receptor agonist SNC80. Br J Pharmacol 2018; 175(6): 891-901.
[http://dx.doi.org/10.1111/bph.14131] [PMID: 29278419]
[130]
Vicente-Sanchez A, Dripps IJ, Tipton AF, et al. Tolerance to high‐internalizing δ opioid receptor agonist is critically mediated by arrestin 2. Br J Pharmacol 2018; 175(14): 3050-9.
[http://dx.doi.org/10.1111/bph.14353] [PMID: 29722902]
[131]
Fossler MJ, Schmith V, Greene SA, et al. A Phase I, Randomized, Single-blind, placebo-controlled, single ascending dose study of the safety, tolerability, and pharmacokinetics of subcutaneous and oral TRV250, a G protein-selective delta receptor agonist, in healthy subjects. CNS Drugs 2020; 34(8): 853-65.
[http://dx.doi.org/10.1007/s40263-020-00738-0] [PMID: 32676977]
[132]
Tepper D, Gepants . Headache 2020; 60(5): 1037-9.
[http://dx.doi.org/10.1111/head.13791] [PMID: 32337726]
[133]
FDA Approved Drug Products. Qulipta (atogepant) tablets for oral use 2021. Available From: https://www.rxabbvie.com/pdf/ qulipta_pi.pdf
[134]
Product Information. UBRELVY (ubrogepant) tablets, for oral use 2019. Available From: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2019/211765s000lbl.pdf
[135]
DailyMed. NURTEC ODT- rimegepant sulfate tablet, orally disintegrating 2023. Available From: https://dailymed.nlm.nih.gov/ dailymed/drugInfo.cfm?setid=9ef08e09-1098-35cc-e053-2a95a-90a3e1d
[136]
DailyMed. AIMOVIG- erenumab-aooe injection, AIMOVIG- erenumab-aooe injection, solution 2023. Available From: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b998ed05-94b0-47fd-b28f-cddd1e128fd8
[137]
Product Information. AJOVYTM (fremanezumab-vfrm) injection, for subcutaneous use 2018. Available From: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761089s000lbl.pdf
[138]
Monteith D, Collins EC, Vandermeulen C, et al. Safety, Tolerability, pharmacokinetics, and pharmacodynamics of the CGRP binding monoclonal antibody LY2951742 (galcanezumab) in healthy volunteers. Front Pharmacol 2017; 8: 740.
[http://dx.doi.org/10.3389/fphar.2017.00740] [PMID: 29089894]
[139]
Product Information. EMGALITY (galcanezumab-gnlm) injection, for subcutaneous use 2018. Available From: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761063s000lbl.pdf
[140]
Product Information. VYEPTITM (eptinezumab-jjmr) injection, for intravenous use 2018. Available From: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761119s000lbl.pdf
[141]
Product Information. ZAVZPRET™ (zavegepant) nasal spray 2023. Available From: https://labeling.pfizer.com/ShowLabeling. aspx?id=19471
[142]
Product Information. REYVOW (lasmiditan) tablets, for oral use controlled substance schedule pending 2021. Available From: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf
[143]
National Institutes of Health. Magnesium Fact Sheet for Health Professionals 2023. Available From: https://ods.od.nih.gov/ factsheets/Magnesium-HealthProfessional/
[144]
Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhäupl KM, Arnold G. High-dose riboflavin treatment is efficacious in migraine prophylaxis: An open study in a tertiary care centre. Eur J Neurol 2004; 11(7): 475-7.
[http://dx.doi.org/10.1111/j.1468-1331.2004.00813.x] [PMID: 15257686]
[145]
Zeng Z, Li Y, Lu S, Huang W, Di W. Efficacy of CoQ10 as supplementation for migraine: A meta-analysis. Acta Neurol Scand 2019; 139(3): 284-93.
[http://dx.doi.org/10.1111/ane.13051] [PMID: 30428123]
[146]
Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Libr 2015; 2020(4): CD002286.
[http://dx.doi.org/10.1002/14651858.CD002286.pub3] [PMID: 25892430]
[147]
Lopresti AL, Smith SJ, Drummond PD. Herbal treatments for migraine: A systematic review of randomised‐controlled studies. Phytother Res 2020; 34(10): 2493-517.
[http://dx.doi.org/10.1002/ptr.6701] [PMID: 32310327]
[148]
American Migraine Foundation. Neuromodulation for Migraine Treatment: An Overview 2021. Available From: https://americanmigrainefoundation.org/resource-library/neuromo-dulation-for-migraine-treatment/
[149]
Xu S, Yu L, Luo X, et al. Manual acupuncture versus sham acupuncture and usual care for prophylaxis of episodic migraine without aura: Multicentre, randomised clinical trial. BMJ 2020; 368: m697.
[http://dx.doi.org/10.1136/bmj.m697] [PMID: 32213509]

Rights & Permissions Print Cite
Article Metrics
51
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy